Brief: Cyclerion Announces CY6463 Clinical Pipeline And Corporate Updates

Korsana Biosciences

24/02/2022 21:12

Feb 24 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION ANNOUNCES CY6463 CLINICAL PIPELINE AND CORPORATE
UPDATES
    * CYCLERION THERAPEUTICS INC - PHASE 2A STUDY IN
MITOCHONDRIAL
ENCEPHALOMYOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES
ENROLLMENT CLOSED
    * CYCLERION THERAPEUTICS INC - PHASE 2A STUDY IN MELAS
TOPLINE
DATA EXPECTED IN Q2 2022
    * CYCLERION THERAPEUTICS - PHASE 1B STUDY IN COGNITIVE
IMPAIRMENT
ASSOCIATED WITH SCHIZOPHRENIA ENROLLMENT ONGOING; TOPLINE DATA
EXPECTED IN H2 2022

Source text for Eikon:  ID:nGNX3Xp97l 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))